{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T03:49:55Z","timestamp":1777348195676,"version":"3.51.4"},"reference-count":131,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T00:00:00Z","timestamp":1628812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19 AG068054, U01 AG051406, P01 AG025204, P01 AG014449, P50 AG16573, P30 AG066468"],"award-info":[{"award-number":["U19 AG068054, U01 AG051406, P01 AG025204, P01 AG014449, P50 AG16573, P30 AG066468"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:p>Individuals with Down syndrome (DS) have a genetic predisposition for amyloid-\u03b2 (A\u03b2) overproduction and earlier onset of A\u03b2 deposits compared to patients with sporadic late-onset Alzheimer\u2019s disease (AD). Positron emission tomography (PET) with Pittsburgh Compound-B (PiB) detects fibrillar A\u03b2 pathology in living people with DS and AD, but its relationship with heterogeneous A\u03b2 forms aggregated within amyloid deposits is not well understood. We performed quantitative <jats:italic>in vitro<\/jats:italic><jats:sup>3<\/jats:sup>H-PiB binding assays and enzyme-linked immunosorbent assays of fibrillar (insoluble) unmodified A\u03b240 and A\u03b242 forms and <jats:italic>N<\/jats:italic>-terminus truncated and pyroglutamate-modified A\u03b2NpE3-40 and A\u03b2NpE3-42 forms in postmortem frontal cortex and precuneus samples from 18 DS cases aged 43\u201363 years and 17 late-onset AD cases aged 62\u201399 years. Both diagnostic groups had frequent neocortical neuritic plaques, while the DS group had more severe vascular amyloid pathology (cerebral amyloid angiopathy, CAA). Compared to the AD group, the DS group had higher levels of A\u03b240 and A\u03b2NpE3-40, while the two groups did not differ by A\u03b242 and A\u03b2NpE3-42 levels. This resulted in lower ratios of A\u03b242\/A\u03b240 and A\u03b2NpE3-42\/A\u03b2NpE3-40 in the DS group compared to the AD group. Correlations of A\u03b242\/A\u03b240 and A\u03b2NpE3-42\/A\u03b2NpE3-40 ratios with CAA severity were strong in DS cases and weak in AD cases. Pyroglutamate-modified A\u03b2 levels were lower than unmodified A\u03b2 levels in both diagnostic groups, but within group proportions of both pyroglutamate-modified A\u03b2 forms relative to both unmodified A\u03b2 forms were lower in the DS group but not in the AD group. The two diagnostic groups did not differ by <jats:sup>3<\/jats:sup>H-PiB binding levels. These results demonstrate that compared to late-onset AD cases, adult DS individuals with similar severity of neocortical neuritic plaques and greater CAA pathology have a preponderance of both pyroglutamate-modified A\u03b2NpE3-40 and unmodified A\u03b240 forms. Despite the distinct molecular profile of A\u03b2 forms and greater vascular amyloidosis in DS cases, cortical <jats:sup>3<\/jats:sup>H-PiB binding does not distinguish between diagnostic groups that are at an advanced level of amyloid plaque pathology. This underscores the need for the development of CAA-selective PET radiopharmaceuticals to detect and track the progression of cerebral vascular amyloid deposits in relation to A\u03b2 plaques in individuals with DS.<\/jats:p>","DOI":"10.3389\/fnagi.2021.728739","type":"journal-article","created":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T12:05:18Z","timestamp":1628856318000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Postmortem Neocortical 3H-PiB Binding and Levels of Unmodified and Pyroglutamate A\u03b2 in Down Syndrome and Sporadic Alzheimer\u2019s Disease"],"prefix":"10.3389","volume":"13","author":[{"given":"Violetta N.","family":"Pivtoraiko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Racic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric E.","family":"Abrahamson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor L.","family":"Villemagne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin L.","family":"Handen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ira T.","family":"Lott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Head","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milos D.","family":"Ikonomovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/dneu.22713","article-title":"Neuropathological correlates of amyloid PET imaging in Down syndrome","volume":"79","author":"Abrahamson","year":"2019","journal-title":"Dev. Neurobiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"P742","DOI":"10.1016\/j.jalz.2016.06.1548","article-title":"Pyroglutamate and full-length amyloid-B concentrations in the superior frontal cortex across clinical stages of Alzheimer\u2019s disease","volume":"12","author":"Abrahamson","year":"2016","journal-title":"Alzheimers Dement."},{"key":"B3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.nucmedbio.2020.05.001","article-title":"Development of a PET radioligand selective for cerebral amyloid angiopathy","volume":"92","author":"Abrahamson","year":"2021","journal-title":"Nucl. Med. Biol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1023\/a:1021910729963","article-title":"Variable deposition of amyloid \u03b2-protein (A \u03b2) with the carboxy-terminus that ends at residue valine40 (A \u03b2 40) in the cerebral cortex of patients with Alzheimer\u2019s disease: a double-labeling immunohistochemical study with antibodies specific for a \u03b2 40 and the A \u03b2 that ends at residues alanine42\/threonine43 (A \u03b2 42)","volume":"22","author":"Akiyama","year":"1997","journal-title":"Neurochem. Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1136\/jnnp.49.8.886","article-title":"Isolated senile plaque cores in Alzheimer\u2019s disease and Down\u2019s syndrome show differences in morphology","volume":"49","author":"Allsop","year":"1986","journal-title":"J. Neurol. Neurosurg Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.neurobiolaging.2017.01.009","article-title":"The Down syndrome brain in the presence and absence of fibrillar \u03b2-amyloidosis","volume":"53","author":"Annus","year":"2017","journal-title":"Neurobiol. Aging"},{"key":"B7","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.jalz.2015.07.490","article-title":"The pattern of amyloid accumulation in the brains of adults with down syndrome","volume":"12","author":"Annus","year":"2016","journal-title":"Alzheimers Dement."},{"key":"B8","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/ana.22112","article-title":"Cerebral amyloid angiopathy pathology and cognitive domains in older persons","volume":"69","author":"Arvanitakis","year":"2011","journal-title":"Ann. Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1001\/archneur.64.3.431","article-title":"Molecular imaging with pittsburgh compound b confirmed at autopsy: a case report","volume":"64","author":"Bacskai","year":"2007","journal-title":"Arch. Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00401-019-01967-4","article-title":"\u03b2-amyloid pathology in human brain microvessel extracts from the parietal cortex: relation with cerebral amyloid angiopathy and Alzheimer\u2019s disease","volume":"137","author":"Bourassa","year":"2019","journal-title":"Acta Neuropathol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00401-006-0127-z","article-title":"Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry","volume":"112","author":"Braak","year":"2006","journal-title":"Acta Neuropathol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"7709","DOI":"10.1523\/JNEUROSCI.2177-05.2005","article-title":"Molecular, structural and functional characterization of Alzheimer\u2019s disease: evidence for a relationship between default activity, amyloid and memory","volume":"25","author":"Buckner","year":"2005","journal-title":"J. Neurosci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.jalz.2017.03.007","article-title":"Cerebral amyloid angiopathy in down syndrome and sporadic and autosomal-dominant Alzheimer\u2019s disease","volume":"13","author":"Carmona-Iragui","year":"2017","journal-title":"Alzheimers Dement."},{"key":"B15","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1136\/jnnp-2017-316851","article-title":"Amyloid-PET burden and regional distribution in cerebral amyloid angiopathy: a systematic review and meta-analysis of biomarker performance","volume":"89","author":"Charidimou","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/aps.2017.28","article-title":"Amyloid \u03b2: structure, biology and structure-based therapeutic development","volume":"38","author":"Chen","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"B17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.neurobiolaging.2020.04.018","article-title":"Association of sleep with cognition and \u03b2 amyloid accumulation in adults with down syndrome","volume":"93","author":"Cody","year":"2020","journal-title":"Neurobiol. Aging"},{"key":"B18","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jalz.2018.01.002","article-title":"Early striatal amyloid deposition distinguishes Down syndrome and autosomal dominant Alzheimer\u2019s disease from late-onset amyloid deposition","volume":"14","author":"Cohen","year":"2018","journal-title":"Alzheimers Dement."},{"key":"B19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/B978-0-12-394816-8.00002-7","article-title":"Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-\u03b2","volume":"64","author":"Cohen","year":"2012","journal-title":"Adv. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.neurobiolaging.2017.04.006","article-title":"Brain-predicted age in Down syndrome is associated with \u03b2 amyloid deposition and cognitive decline","volume":"56","author":"Cole","year":"2017","journal-title":"Neurobiol. Aging"},{"key":"B21","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1093\/jnen\/nlab039","article-title":"The cryo-EM effect: structural biology of neurodegenerative disease aggregates","volume":"80","author":"Creekmore","year":"2021","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"7405","DOI":"10.1021\/bi800250p","article-title":"Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-\u03b2","volume":"47","author":"Cynis","year":"2008","journal-title":"Biochemistry"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4996","DOI":"10.1039\/c6sc04797a","article-title":"Pyroglutamate-modified A\u03b2 (3\u201342) affects aggregation kinetics of A\u03b2 (1\u201342) by accelerating primary and secondary pathways","volume":"8","author":"Dammers","year":"2017","journal-title":"Chem. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40478-018-0559-4","article-title":"The age of onset and evolution of braak tangle stage and thal amyloid pathology of Alzheimer\u2019s disease in individuals with down syndrome","volume":"6","author":"Davidson","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"key":"B25","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.neuron.2012.10.029","article-title":"A plaque-specific antibody clears existing \u03b2-amyloid plaques in Alzheimer\u2019s disease mice","volume":"76","author":"Demattos","year":"2012","journal-title":"Neuron"},{"key":"B26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s00401-004-0950-z","article-title":"Required techniques and useful molecular markers in the neuropathologic diagnosis of neurodegenerative diseases","volume":"109","author":"Dickson","year":"2005","journal-title":"Acta Neuropathol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/00005072-199704000-00001","article-title":"The pathogenesis of senile plaques","volume":"56","author":"Dickson","year":"1997","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/ana.22099","article-title":"Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy","volume":"68","author":"Dierksen","year":"2010","journal-title":"Ann. Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1001\/jamaneurol.2013.420","article-title":"Does a positive pittsburgh compound B scan in a patient with dementia equal Alzheimer disease?","volume":"70","author":"Ducharme","year":"2013","journal-title":"JAMA Neurol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ajpath.2013.05.005","article-title":"Pyroglutamate-3 amyloid-\u03b2 deposition in the brains of humans, non-human primates, canines and Alzheimer disease-like transgenic mouse models","volume":"183","author":"Frost","year":"2013","journal-title":"Am. J. Pathol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1016\/j.neurobiolaging.2015.08.021","article-title":"An anti-pyroglutamate-3 A\u03b2 vaccine reduces plaques and improves cognition in APPswe\/PS1DeltaE9 mice","volume":"36","author":"Frost","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"B32","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.neulet.2019.02.033","article-title":"A distinct brain \u03b2 amyloid signature in cerebral amyloid angiopathy compared to Alzheimer\u2019s disease","volume":"701","author":"Gkanatsiou","year":"2019","journal-title":"Neurosci. Lett."},{"key":"B33","doi-asserted-by":"publisher","first-page":"135894","DOI":"10.1016\/j.neulet.2021.135894","article-title":"Characterization of monomeric and soluble aggregated A\u03b2 in Down\u2019s syndrome and Alzheimer\u2019s disease brains","volume":"754","author":"Gkanatsiou","year":"2021","journal-title":"Neurosci. Lett."},{"key":"B34","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/s0925-4439(00)00043-0","article-title":"Biochemical detection of A\u03b2 isoforms: implications for pathogenesis, diagnosis and treatment of Alzheimer\u2019s disease","volume":"1502","author":"Golde","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"key":"B35","doi-asserted-by":"publisher","first-page":"7013","DOI":"10.1186\/s40478-021-01225-3","article-title":"Amyloid \u03b2 protein (A \u03b2) in Alzheimer\u2019s disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at a \u03b2 40 or A \u03b2 42(43)","volume":"270","author":"Gravina","year":"1995","journal-title":"J. Biol. Chem."},{"key":"B36","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/ana.21528","article-title":"Detection of isolated cerebrovascular \u03b2-amyloid with Pittsburgh compound B","volume":"64","author":"Greenberg","year":"2008","journal-title":"Ann. Neurol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.biocel.2010.08.015","article-title":"Pyroglutamate-A\u03b2: role in the natural history of Alzheimer\u2019s disease","volume":"42","author":"Gunn","year":"2010","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.neuroscience.2006.08.027","article-title":"High sensitivity analysis of amyloid-\u03b2 peptide composition in amyloid deposits from human and PS2APP mouse brain","volume":"143","author":"Guntert","year":"2006","journal-title":"Neuroscience"},{"key":"B39","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.jalz.2011.09.229","article-title":"Imaging brain amyloid in nondemented young adults with Down syndrome using pittsburgh compound B","volume":"8","author":"Handen","year":"2012","journal-title":"Alzheimers Dement."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e12065","DOI":"10.1002\/dad2.12065","article-title":"The Alzheimer \u2019s biomarker consortium-down syndrome: rationale and methodology","volume":"12","author":"Handen","year":"2020","journal-title":"Alzheimers Dement. (Amst)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1006\/bbrc.2000.3490","article-title":"Amyloid \u03b2 protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer\u2019s disease brain","volume":"276","author":"Harigaya","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B42","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.neurobiolaging.2017.05.019","article-title":"Cognitive decline and brain amyloid-\u03b2 accumulation across 3 years in adults with down syndrome","volume":"58","author":"Hartley","year":"2017","journal-title":"Neurobiol. Aging"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e12096","DOI":"10.1002\/dad2.12096","article-title":"Cognitive indicators of transition to preclinical and prodromal stages of Alzheimer\u2019s disease in Down syndrome","volume":"12","author":"Hartley","year":"2020","journal-title":"Alzheimers Dement. (Amst)"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1093\/brain\/awu173","article-title":"Cognitive functioning in relation to brain amyloid-\u03b2 in healthy adults with Down syndrome","volume":"137","author":"Hartley","year":"2014","journal-title":"Brain"},{"key":"B45","doi-asserted-by":"publisher","first-page":"10871","DOI":"10.1021\/bi990563r","article-title":"The A \u03b2 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater \u03b2-sheet forming and aggregation propensities in vitro than full-length A \u03b2","volume":"38","author":"He","year":"1999","journal-title":"Biochemistry"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1016\/S0140-6736(20)30916-8","article-title":"Biomarkers in down syndrome can help us understand Alzheimer\u2019s disease","volume":"395","author":"Head","year":"2020","journal-title":"Lancet"},{"key":"B47","doi-asserted-by":"publisher","first-page":"18","DOI":"10.2174\/1567205012666151020114607","article-title":"Aging in down syndrome and the development of Alzheimer\u2019s disease neuropathology","volume":"13","author":"Head","year":"2016","journal-title":"Curr. Alzheimer Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s40478-017-0499-4","article-title":"Cerebrovascular pathology in down syndrome and Alzheimer disease","volume":"5","author":"Head","year":"2017","journal-title":"Acta Neuropathol. Commun."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.3390\/jcm10091907","article-title":"Cross-sectional exploration of plasma biomarkers of Alzheimer\u2019s disease in down syndrome: early data from the longitudinal investigation for enhancing down syndrome research (LIFE-DSR) study","volume":"10","author":"Hendrix","year":"2021","journal-title":"J. Clin. Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1097\/00005072-199811000-00012","article-title":"Quantification of modified amyloid \u03b2 peptides in Alzheimer disease and Down syndrome brains","volume":"57","author":"Hosoda","year":"1998","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00401-020-02175-1","article-title":"Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-\u03b2 plaques in Alzheimer\u2019s disease","volume":"140","author":"Ikonomovic","year":"2020","journal-title":"Acta Neuropathol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1093\/brain\/awn016","article-title":"Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer\u2019s disease","volume":"131","author":"Ikonomovic","year":"2008","journal-title":"Brain"},{"key":"B53","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/ana.410370305","article-title":"Amyloid \u03b2 protein (A \u03b2) deposition: a \u03b2 42(43) precedes A \u03b2 40 in Down syndrome","volume":"37","author":"Iwatsubo","year":"1995","journal-title":"Ann. Neurol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0896-6273(94)90458-8","article-title":"Visualization of A \u03b2 42(43) and A \u03b2 40 in senile plaques with end-specific A \u03b2 monoclonals: evidence that an initially deposited species is A \u03b2 42 (43)","volume":"13","author":"Iwatsubo","year":"1994","journal-title":"Neuron"},{"key":"B55","first-page":"1823","article-title":"Full-length amyloid-\u03b2 (1\u201342(43)) and amino-terminally modified and truncated amyloid-\u03b2 42(43) deposit in diffuse plaques","volume":"149","author":"Iwatsubo","year":"1996","journal-title":"Am. J. Pathol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1021\/bi00069a001","article-title":"The carboxy terminus of the \u03b2 amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer\u2019s disease","volume":"32","author":"Jarrett","year":"1993","journal-title":"Biochemistry"},{"key":"B57","doi-asserted-by":"publisher","first-page":"38825","DOI":"10.1074\/jbc.R111.288308","article-title":"Pyroglutamate amyloid-\u03b2 (A\u03b2): a hatchet man in Alzheimer disease","volume":"286","author":"Jawhar","year":"2011","journal-title":"J. Biol. Chem."},{"key":"B58","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/ana.21164","article-title":"Imaging of amyloid burden and distribution in cerebral amyloid angiopathy","volume":"62","author":"Johnson","year":"2007","journal-title":"Ann. Neurol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1212\/WNL.0b013e318233b33d","article-title":"Age-related changes in the default mode network are more advanced in Alzheimer disease","volume":"77","author":"Jones","year":"2011","journal-title":"Neurology"},{"key":"B60","first-page":"113","article-title":"Detection, quantitation of amyloid \u03b2-peptide with 2 monoclonal antibodies","volume":"7","author":"Kim","year":"1990","journal-title":"Neurosci. Res. Commun."},{"key":"B61","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer\u2019s disease with pittsburgh compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann. Neurol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1006\/bbrc.1997.7083","article-title":"Isolation, chemical characterization and quantitation of A \u03b2 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits","volume":"237","author":"Kuo","year":"1997","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B63","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1001\/archneurol.2011.36","article-title":"Using positron emission tomography and Carbon 11-labeled pittsburgh compound B to image brain fibrillar \u03b2-amyloid in adults with down syndrome: safety, acceptability and feasibility","volume":"68","author":"Landt","year":"2011","journal-title":"Arch. Neurol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jalz.2015.05.013","article-title":"The effects of normal aging on amyloid-\u03b2 deposition in nondemented adults with Down syndrome as imaged by carbon 11-labeled pittsburgh compound B","volume":"12","author":"Lao","year":"2016","journal-title":"Alzheimers Dement."},{"key":"B65","doi-asserted-by":"publisher","first-page":"631","DOI":"10.3233\/JAD-170720","article-title":"Alzheimer-like pattern of hypometabolism emerges with elevated amyloid-\u03b2 burden in down syndrome","volume":"61","author":"Lao","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.dadm.2017.05.001","article-title":"Longitudinal changes in amyloid positron emission tomography and volumetric magnetic resonance imaging in the nondemented down syndrome population","volume":"9","author":"Lao","year":"2017","journal-title":"Alzheimers Dement. (Amst)"},{"key":"B67","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1006\/nbdi.1996.0003","article-title":"Sequence of deposition of heterogeneous amyloid \u03b2-peptides and APOE in down syndrome: implications for initial events in amyloid plaque formation","volume":"3","author":"Lemere","year":"1996","journal-title":"Neurobiol. Dis."},{"key":"B68","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.neurobiolaging.2017.03.005","article-title":"Down syndrome: age-dependence of PiB binding in postmortem frontal cortex across the lifespan","volume":"54","author":"LeVine","year":"2017","journal-title":"Neurobiol. Aging"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1093\/brain\/awm191","article-title":"PIB is a non-specific imaging marker of amyloid-\u03b2 (A\u03b2) peptide-related cerebral amyloidosis","volume":"130","author":"Lockhart","year":"2007","journal-title":"Brain"},{"key":"B70","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41582-018-0132-6","article-title":"Dementia in down syndrome: unique insights for Alzheimer disease research","volume":"15","author":"Lott","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1212\/WNL.0b013e3181cef7e3","article-title":"11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage","volume":"74","author":"Ly","year":"2010","journal-title":"Neurology"},{"key":"B72","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.dadm.2019.04.006","article-title":"Longitudinal trajectories of amyloid deposition, cortical thickness and tau in Down syndrome: a deep-phenotyping case report","volume":"11","author":"Mak","year":"","journal-title":"Alzheimers Dement. (Amst)"},{"key":"B73","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.neurobiolaging.2019.02.018","article-title":"Delineating the topography of amyloid-associated cortical atrophy in Down syndrome","volume":"80","author":"Mak","year":"","journal-title":"Neurobiol. Aging"},{"key":"B74","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/0022-510x(89)90019-1","article-title":"The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down\u2019s syndrome","volume":"89","author":"Mann","year":"1989","journal-title":"J. Neurol. Sci."},{"key":"B75","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1006\/neur.1996.0017","article-title":"Diffuse plaques in the cerebellum and corpus striatum in Down\u2019s syndrome contain amyloid beta protein (A beta) only in the form of A beta 42 (43)","volume":"5","author":"Mann","year":"1996","journal-title":"Neurodegeneration"},{"key":"B76","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1365-2559.1988.tb02018.x","article-title":"Alzheimer\u2019s disease and Down\u2019s syndrome","volume":"13","author":"Mann","year":"1988","journal-title":"Histopathology"},{"key":"B77","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00401-018-1866-3","article-title":"Patterns and severity of vascular amyloid in Alzheimer\u2019s disease associated with duplications and missense mutations in APP gene, Down syndrome and sporadic Alzheimer\u2019s disease","volume":"136","author":"Mann","year":"2018","journal-title":"Acta Neuropathol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","article-title":"Amyloid plaque core protein in Alzheimer disease and Down syndrome","volume":"82","author":"Masters","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"B79","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1053\/j.semnuclmed.2017.06.003","article-title":"Small-molecule PET tracers for imaging proteinopathies","volume":"47","author":"Mathis","year":"2017","journal-title":"Semin. Nucl. Med."},{"key":"B80","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/wnl.34.7.939","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer\u2019s disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"B81","doi-asserted-by":"publisher","first-page":"6719","DOI":"10.1074\/jbc.RA118.006604","article-title":"Pyroglutamation of amyloid-betax-42 (Abetax-42) followed by Abeta140 deposition underlies plaque polymorphism in progressing Alzheimer\u2019s disease pathology","volume":"294","author":"Michno","year":"2019","journal-title":"J. Biol. Chem."},{"key":"B82","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/dneu.22677","article-title":"Leisure activity, brain beta-amyloid and episodic memory in adults with Down syndrome","volume":"79","author":"Mihaila","year":"2019","journal-title":"Dev. Neurobiol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1006\/abbi.1993.1112","article-title":"Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer\u2019s disease","volume":"301","author":"Miller","year":"1993","journal-title":"Arch. Biochem. Biophys."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B85","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1212\/wnl.41.4.479","article-title":"The consortium to establish a registry for Alzheimer\u2019s disease (CERAD). part II. standardization of the neuropathologic assessment of Alzheimer\u2019s disease","volume":"41","author":"Mirra","year":"1991","journal-title":"Neurology"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","article-title":"National institute on aging-Alzheimer\u2019s association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: a practical approach","volume":"123","author":"Montine","year":"2012","journal-title":"Acta Neuropathol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3233\/JAD-131535","article-title":"Glutaminyl cyclase in human cortex: correlation with (pGlu)-amyloid-beta load and cognitive decline in Alzheimer\u2019s disease","volume":"39","author":"Morawski","year":"2104","journal-title":"J. Alzheimers Dis."},{"key":"B88","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3109\/13506120208995241","article-title":"Intraneuronal Abeta42 accumulation in Down syndrome brain","volume":"9","author":"Mori","year":"2002","journal-title":"Amyloid"},{"key":"B89","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/bmj.2.6081.226","article-title":"Down\u2019s syndrome: an atheroma-free model","volume":"2","author":"Murdoch","year":"1977","journal-title":"Br. Med. J."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1093\/brain\/awv050","article-title":"Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer\u2019s disease spectrum","volume":"138","author":"Murray","year":"2015","journal-title":"Brain"},{"key":"B91","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.nicl.2017.10.022","article-title":"Neuroimaging and other modalities to assess Alzheimer\u2019s disease in Down syndrome","volume":"17","author":"Neale","year":"2018","journal-title":"Neuroimage Clin."},{"key":"B92","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1001\/archneur.1995.00540310076019","article-title":"Cerebral infarction in Alzheimer\u2019s disease is associated with severe amyloid angiopathy and hypertension","volume":"52","author":"Olichney","year":"1995","journal-title":"Arch. Neurol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1046\/j.1471-4159.1994.62031062.x","article-title":"Down\u2019s syndrome: up-regulation of beta-amyloid protein precursor and tau mRNAs and their defective coordination","volume":"62","author":"Oyama","year":"1994","journal-title":"J. Neurochem."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41467-017-01150-x","article-title":"Earliest accumulation of beta-amyloid occurs within the default-mode network and concurrently affects brain connectivity","volume":"8","author":"Palmqvist","year":"2017","journal-title":"Nat. Commun."},{"key":"B95","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00401-019-01965-6","article-title":"Frontal cortex and striatal cellular and molecular pathobiology in individuals with Down syndrome with and without dementia","volume":"137","author":"Perez","year":"2019","journal-title":"Acta Neuropathol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3233\/JAD-201167","article-title":"plasma total-tau and neurofilament light chain as diagnostic biomarkers of Alzheimer\u2019s disease dementia and mild cognitive impairment in adults with Down syndrome","volume":"79","author":"Petersen","year":"2021","journal-title":"J. Alzheimers Dis."},{"key":"B97","doi-asserted-by":"publisher","first-page":"e12039","DOI":"10.1002\/dad2.12039","article-title":"Proteomic profiles for Alzheimer\u2019s disease and mild cognitive impairment among adults with Down syndrome spanning serum and plasma: an Alzheimer\u2019s biomarker consortium-Down syndrome (ABC-DS) study","volume":"12","author":"Petersen","year":"2020","journal-title":"Alzheimers Dement. (Amst)"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1212\/wnl.58.11.1629","article-title":"Cerebral amyloid angiopathy and cognitive function: the HAAS autopsy study","volume":"58","author":"Pfeifer","year":"2002","journal-title":"Neurology"},{"key":"B99","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.neurobiolaging.2014.06.021","article-title":"Cortical pyroglutamate amyloid-beta levels and cognitive decline in Alzheimer\u2019s disease","volume":"36","author":"Pivtoraiko","year":"2015","journal-title":"Neurobiol. Aging."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.3233\/JAD-190625","article-title":"Florbetapir regional distribution in cerebral amyloid angiopathy and Alzheimer\u2019s disease: a PET study","volume":"73","author":"Planton","year":"2020","journal-title":"J. Alzheimers Dis."},{"key":"B101","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1001\/jamaneurol.2013.1321","article-title":"White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease","volume":"70","author":"Provenzano","year":"2013","journal-title":"JAMA Neurol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1590\/1516-3180.2016.0057180316","article-title":"Blood pressure levels and body mass index in brazilian adults with Down syndrome","volume":"134","author":"Pucci","year":"2016","journal-title":"Sao Paulo Med. J."},{"key":"B103","doi-asserted-by":"publisher","first-page":"e12062","DOI":"10.1002\/dad2.12062","article-title":"The AT(N) framework for Alzheimer\u2019s disease in adults with Down syndrome","volume":"12","author":"Rafii","year":"2020","journal-title":"Alzheimers Dement. (Amst)"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuint.2017.08.007","article-title":"APP\/Abeta structural diversity and Alzheimer\u2019s disease pathogenesis","volume":"110","author":"Roher","year":"2017","journal-title":"Neurochem. Int."},{"key":"B105","doi-asserted-by":"publisher","first-page":"10836","DOI":"10.1073\/pnas.90.22.10836","article-title":"beta-Amyloid-(1\u201342) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease","volume":"90","author":"Roher","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1111\/j.1471-4159.1993.tb09834.x","article-title":"Morphological and biochemical analyses of amyloid plaque core proteins purified from Alzheimer disease brain tissue","volume":"61","author":"Roher","year":"1993","journal-title":"J. Neurochem."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1212\/01.wnl.0000261919.22630.ea","article-title":"Imaging beta-amyloid burden in aging and dementia","volume":"68","author":"Rowe","year":"2007","journal-title":"Neurology"},{"key":"B109","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/s0014-5793(97)00564-4","article-title":"Heterogeneity of water-soluble amyloid beta-peptide in Alzheimer\u2019s disease and Down\u2019s syndrome brains","volume":"409","author":"Russo","year":"1997","journal-title":"FEBS Lett."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1001\/archneurol.2011.535","article-title":"Positron emission tomography and neuropathologic estimates of fibrillar amyloid-beta in a patient with Down syndrome and Alzheimer disease","volume":"68","author":"Sabbagh","year":"2011","journal-title":"Arch. Neurol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/0896-6273(95)90301-1","article-title":"Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques","volume":"14","author":"Saido","year":"1995","journal-title":"Neuron"},{"key":"B112","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/0304-3940(96)12970-0","article-title":"Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain","volume":"215","author":"Saido","year":"1996","journal-title":"Neurosci. Lett."},{"key":"B113","doi-asserted-by":"publisher","first-page":"12393","DOI":"10.1021\/bi0612667","article-title":"On the seeding and oligomerization of pGlu-amyloid peptides (in vitro)","volume":"45","author":"Schilling","year":"2006","journal-title":"Biochemistry"},{"key":"B114","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1038\/nm.1872","article-title":"Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer \u2019s disease-like pathology","volume":"14","author":"Schilling","year":"2008","journal-title":"Nat. Med."},{"key":"B115","doi-asserted-by":"publisher","first-page":"7072","DOI":"10.1021\/bi900818a","article-title":"Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides","volume":"48","author":"Schlenzig","year":"2009","journal-title":"Biochemistry"},{"key":"B116","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.nicl.2016.11.008","article-title":"Regional correlations between [(11)C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort","volume":"13","author":"Seo","year":"2017","journal-title":"Neuroimage Clin."},{"key":"B117","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.neulet.2011.09.071","article-title":"Pyroglutamate-Abeta 3 and 11 colocalize in amyloid plaques in Alzheimer\u2019s disease cerebral cortex with pyroglutamate-Abeta 11 forming the central core","volume":"505","author":"Sullivan","year":"2011","journal-title":"Neurosci. Lett."},{"key":"B118","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nm0196-93","article-title":"Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down\u2019s syndrome","volume":"2","author":"Teller","year":"1996","journal-title":"Nat. Med."},{"key":"B119","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.neurobiolaging.2018.09.030","article-title":"Comparison of longitudinal Abeta in nondemented elderly and Down syndrome","volume":"73","author":"Tudorascu","year":"2019","journal-title":"Neurobiol. Aging."},{"key":"B120","doi-asserted-by":"publisher","first-page":"e12096","DOI":"10.1002\/trc2.12096","article-title":"Relationship of amyloid beta and neurofibrillary tau deposition in neurodegeneration in aging Down syndrome (NiAD) study at baseline","volume":"6","author":"Tudorascu","year":"2020","journal-title":"Alzheimers Dement. (N Y)"},{"key":"B121","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1148\/radiol.2020200028","article-title":"Molecular imaging approaches in dementia","volume":"298","author":"Villemagne","year":"2021","journal-title":"Radiology"},{"key":"B122","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1161\/01.str.18.2.311","article-title":"Cerebral amyloid angiopathy. A critical review","volume":"18","author":"Vinters","year":"1987","journal-title":"Stroke"},{"key":"B123","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/ana.22516","article-title":"Cerebral amyloid angiopathy in the elderly","volume":"70","author":"Viswanathan","year":"2011","journal-title":"Ann. Neurol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.bbadis.2015.11.007","article-title":"Cerebrovascular contributions to aging and Alzheimer\u2019s disease in Down syndrome","volume":"1862","author":"Wilcock","year":"2016","journal-title":"Biochim. Biophys Acta."},{"key":"B125","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.1002\/hbm.24720","article-title":"Differential effects of Down\u2019s syndrome and Alzheimer \u2019s neuropathology on default mode connectivity","volume":"40","author":"Wilson","year":"2019","journal-title":"Hum. Brain Mapp."},{"key":"B126","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/ana.410170310","article-title":"Occurrence of neuropathological changes and dementia of Alzheimer\u2019s disease in Down\u2019s syndrome","volume":"17","author":"Wisniewski","year":"1985","journal-title":"Ann. Neurol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5853\/jos.2015.17.1.17","article-title":"Cerebral amyloid angiopathy: emerging concepts","volume":"17","author":"Yamada","year":"2015","journal-title":"J. Stroke"},{"key":"B128","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/jnc.13887","article-title":"Pittsburgh compound-B (PiB) binds amyloid beta-protein protofibrils","volume":"140","author":"Yamin","year":"2017","journal-title":"J. Neurochem."},{"key":"B129","doi-asserted-by":"publisher","first-page":"e12020","DOI":"10.1002\/dad2.12020","article-title":"Amyloid accumulation in Down syndrome measured with amyloid load","volume":"12","author":"Zammit","year":"2020","journal-title":"Alzheimers Dement. (Amst)"},{"key":"B130","doi-asserted-by":"publisher","first-page":"117728","DOI":"10.1016\/j.neuroimage.2021.117728","article-title":"PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid-beta accumulation during Alzheimer\u2019s disease progression in Down syndrome","volume":"228","author":"Zammit","year":"2021","journal-title":"Neuroimage"},{"key":"B131","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0074-7750(08)00004-9","article-title":"Alzheimer\u2019s disease in adults with Down syndrome","volume":"36","author":"Zigman","year":"2008","journal-title":"Int. Rev. Res. Ment. Retard."},{"key":"B132","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1352\/0895-8017(2002)107<0161:IATPOA>2.0.CO;2","article-title":"Incidence and temporal patterns of adaptive behavior change in adults with mental retardation","volume":"107","author":"Zigman","year":"2002","journal-title":"Am. J. Ment. Retard."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2021.728739\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T12:37:01Z","timestamp":1629290221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2021.728739\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,13]]},"references-count":131,"alternative-id":["10.3389\/fnagi.2021.728739"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2021.728739","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,13]]},"article-number":"728739"}}